Rapid Itch Relief: Nemluvio Demonstrates 48-Hour Efficacy in Major Clinical Trials

Galderma Group AG has unveiled compelling clinical evidence that Nemluvio, its lead dermatological treatment, delivers measurable itch improvement and sleep restoration within just two days of administration. The breakthrough findings, drawn from extensive post-hoc analyses of the ARCADIA and OLYMPIA phase III trial programs, have been formally published in the Journal of the European Academy of Dermatology and Venereology.

The Clinical Evidence: Swift Action Where It Matters

The data speaks volumes about Nemluvio’s speed of action. In atopic dermatitis patients, nemolizumab—the active component in Nemluvio—reduced itch intensity by 10.7% within 48 hours, substantially outpacing the 2.9% reduction observed in the placebo group. For prurigo nodularis sufferers, the performance gap widened even further: 17.2% itch reduction versus 3.7% with placebo over the same timeframe.

Sleep quality improvements tracked similarly impressive patterns. Atopic dermatitis patients experienced approximately 9.9% improvement in sleep disturbances compared to 4.6% for placebo, while prurigo nodularis participants saw 13.4% improvement against 4.3% in controls. By day 14, approximately one-quarter of atopic dermatitis patients and over one-third of prurigo nodularis patients had achieved clinically significant responses across both itch and sleep metrics.

Understanding the Target Conditions

Both atopic dermatitis and prurigo nodularis represent chronic inflammatory skin diseases marked by severe itching and characteristic skin lesions. These conditions significantly impair quality of life, with sleep disruption being a particularly debilitating secondary effect. The ARCADIA trials enrolled more than 1,700 participants aged 12 and older with moderate-to-severe atopic dermatitis, while the OLYMPIA program evaluated 560 adults with moderate-to-severe prurigo nodularis across 16 to 24-week treatment periods.

Market Momentum and Regulatory Status

Nemluvio received US regulatory clearance for prurigo nodularis in August 2024, followed by approval for adolescent and adult atopic dermatitis patients in December 2024. Originally developed by Chugai Pharmaceutical, Galderma holds exclusive development and commercialization rights across most global markets outside Japan and Taiwan. The drug generated $263 million in net sales during the first nine months of 2025, signaling strong market adoption and driving Galderma to raise full-year revenue guidance to 17.0-17.7% from its previously projected 12-14% range.

Galderma’s stock currently trades at 160.50 Swiss francs, down 0.93% in recent activity, reflecting broader market conditions rather than any specific trial-related concerns.